Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (Nasdaq: MRVI) provides products and services used in developing drugs, therapeutics, vaccines and diagnostics, and in research on human disease. Its customers include biopharmaceutical and biotechnology companies, life science research organizations, academic institutions and… From the company’s description.
Over the twelve months to Sep 30, 2026, Maravai LifeSciences Holdings, Inc. reported revenue of $213.00M, up 10.8% from a year earlier, and a net loss of $115.02M. Its operating margin was −45.4%, and operations used $5.10M in cash. In fiscal 2025, it reported revenue of $185.74M, down 28.3% from fiscal 2024, and a net loss of $230.76M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Maravai LifeSciences Holdings, Inc. does
In the company’s own words
Maravai LifeSciences Holdings, Inc. (Nasdaq: MRVI) provides products and services used in developing drugs, therapeutics, vaccines and diagnostics, and in research on human disease. Its customers include biopharmaceutical and biotechnology companies, life science research organizations, academic institutions and diagnostics companies. Maravai operates through two reportable segments: TriLink, which supplies complex nucleic acids, mRNA manufacturing services, oligonucleotides, synthesis inputs, specialty enzymes and related technologies, and Cygnus, which provides biologics safety testing products and services, including host cell protein assays, impurity detection kits, viral clearance prediction tools and custom analytical services. TriLink generated 64% of revenue and Cygnus 36% in fiscal 2025. Key brands and technologies include CleanCap® mRNA capping, ModTail™ poly(A) tail modification and Cygnus’s MockV® viral clearance tools. The company serves customers directly and through distributors in approximately 60 countries. It had 435 full-time employees globally as of December 31, 2025. Its website is www.maravai.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1823239
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Maravai LifeSciences Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Maravai LifeSciences Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Maravai LifeSciences Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Maravai LifeSciences Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Maravai LifeSciences Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”